Tag Archives: fighting legal marijuana

Legal Weed Is Hurting Beer Sales

It would appear that citizens of states with legal marijuana are switching out their beers for joints: A study from research firm Cowen & Company into the beer industries of Washington, Oregon, and Colorado asserts that those states’ beer industries are “underperforming.”

Craft beer industry news site BrewBound has some of the report’s details. “Domestic brewers” (that is, Big Beer) have seen the largest drops, with so-called premium brews (Coors Light, Bud Light) going down 4.4 percent in terms of the volume being sold. Economy brews (the regular, “non-fancy” forms of mainstream beers such as Budweiser or Coors) fell 2.4 percent.

Craft beer isn’t totally immune. The report suggests craft beer continues to grow in these three states (all of which are known for their robust microbrewing scenes), but those smaller breweries aren’t doing as well as their peers in other parts of the nation. However, the U.S. craft brewing scene was already slowing down, so that’s not entirely the fault of cannabis.

The epicenter of this trading-beer-for-weed phenomenon has been Denver, where beer volumes dropped by 6.4 percent Strangely, the report notes that import beers are relatively unaffected, indicating that lighting up a joint and drinking a Corona may be a more popular pastime.

Since only three states were studied this perhaps isn’t the most definitive look into the trend — but as marijuana goes on sale in several more states in the near future, there will be plenty of opportunities to see what legal weed might do to the beer industry.

sourced from – http://www.eater.com/2016/12/5/13847656/legal-pot-beer-sales-down

Why pharma companies are fighting legal marijuana

FewerPillsChart

There’s a body of research showing that painkiller abuse and overdose are lower in states with medical marijuana laws. These studies have generally assumed that when medical marijuana is available, pain patients are increasingly choosing pot over powerful and deadly prescription narcotics. But that’s always been just an assumption.

Now a new study, released in the journal Health Affairs, validates these findings by providing clear evidence of a missing link in the causal chain running from medical marijuana to falling overdoses. Ashley and W. David Bradford, a daughter-father pair of researchers at the University of Georgia, scoured the database of all prescription drugs paid for under Medicare Part D from 2010 to 2013.

They found that, in the 17 states with a medical-marijuana law in place by 2013, prescriptions for painkillers and other classes of drugs fell sharply compared with states that did not have a medical-marijuana law. The drops were quite significant: In medical-marijuana states, the average doctor prescribed 265 fewer doses of antidepressants each year, 486 fewer doses of seizure medication, 541 fewer anti-nausea doses and 562 fewer doses of anti-anxiety medication.

But most strikingly, the typical physician in a medical-marijuana state prescribed 1,826 fewer doses of painkillers in a given year.

These conditions are among those for which medical marijuana is most often approved under state laws. So as a sanity check, the Bradfords ran a similar analysis on drug categories that pot typically is not recommended for — blood thinners, anti-viral drugs and antibiotics. And on those drugs, they found no changes in prescribing patterns after the passage of marijuana laws.

“This provides strong evidence that the observed shifts in prescribing patterns were in fact due to the passage of the medical marijuana laws,” they write.

In a news release, lead author Ashley Bradford wrote, “The results suggest people are really using marijuana as medicine and not just using it for recreational purposes.”

One interesting wrinkle in the data is glaucoma, for which there was a small increase in demand for traditional drugs in medical-marijuana states. It’s routinely listed as an approved condition under medical-marijuana laws, and studies have shown that marijuana provides some degree of temporary relief for its symptoms.

The Bradfords hypothesize that the short duration of the glaucoma relief provided by marijuana — roughly an hour or so — may actually stimulate more demand in traditional glaucoma medications. Glaucoma patients may experience some short-term relief from marijuana, which may prompt them to seek other, robust treatment options from their doctors.

The tanking numbers for painkiller prescriptions in medical marijuana states are likely to cause some concern among pharmaceutical companies. These companies have long been at the forefront of opposition to marijuana reform, funding research by anti-pot academics and funneling dollars to groups, such as the Community Anti-Drug Coalitions of America, that oppose marijuana legalization.

Read Full Article – https://www.washingtonpost.com/news/wonk/wp/2016/07/13/one-striking-chart-shows-why-pharma-companies-are-fighting-legal-marijuana/